Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 20Gastrointestinal Stromal Tumors 9Kidney Neoplasms 6Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Kidney Diseases 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urologic Neoplasms 1Prostatic Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Patient Preference 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Renal Cancer 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 4Gemcitabine 4padeliporfin 3napabucasin 3Pemetrexed 3Paclitaxel 3Drug Therapy 3Cisplatin 3Carboplatin 3130-nm albumin-bound paclitaxel 3ribociclib 2palbociclib 2Mitomycin 2Gonadotropin-Releasing Hormone 2Fluorouracil 2Bevacizumab 2Anastrozole 2Albumin-Bound Paclitaxel 2AZD9833 2valrubicin 1selinexor 1pralsetinib 1patritumab 1palladium-bacteriopheophorbide 1linifanib 1ipatasertib 1enfortumab vedotin 1camrelizumab 1atezolizumab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms by Site × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡